Latest market price
165.00
-9.00-5.17%
ALNYQT33Alnylam Pharmaceuticals, Inc.·NASDAQ
165.00-5.17%

Latest SEC Filings

Form category
DescriptionFilingDocument
Oct 30, 2026SC 13GBeneficial ownership statement (passive)
Oct 29, 20268-KCurrent report
Oct 29, 202610-QQuarterly report
Oct 06, 20264Statement of changes in beneficial ownership
Sep 22, 20264Statement of changes in beneficial ownership
Jul 30, 20268-KCurrent report
Jul 30, 202610-QQuarterly report
Jun 03, 20264Statement of changes in beneficial ownership
Jun 03, 20264Statement of changes in beneficial ownership
Jun 03, 20263Initial statement of beneficial ownership
Jun 01, 2026144Notice of proposed sale of restricted securities
May 27, 20268-KCurrent report
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 22, 20264Statement of changes in beneficial ownership
May 14, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 14, 2026SC 13G/ABeneficial ownership statement (passive, amended)
May 14, 20264Statement of changes in beneficial ownership
May 06, 2026SC 13G/ABeneficial ownership statement (passive, amended)